Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 11, pp 1917–1926 | Cite as

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy

  • George Dranitsaris
  • Susanne Schmitz
  • Reuben J. Broom
Original Paper

Abstract

Background

Patients with metastatic renal cell carcinoma (mRCC) and a good performance status typically receive an anti-vascular endothelial growth factor receptor (VEGFR) TKI (sunitinib or pazopanib) as initial therapy. Upon disease progression or intolerance, there are four orally administered agents approved in the second-line setting (including cytokine-refractory). However, head-to-head comparative trial data are limited. In this study, an indirect statistical comparison of safety and efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus in second-line therapy mRCC.

Methods

A systematic review of major databases was conducted from January 2005 to June 2013 for randomized controlled trials (RCTs) evaluating at least one of the four agents in second-line mRCC. Bayesian mixed treatment comparison models were fitted to assess relative effectiveness on multiple endpoints such as objective response rates, dose-limiting grade III/IV toxicities, treatment discontinuations and progression-free survival (PFS).

Results

Four RCTs met the inclusion criteria. All four agents seem able to induce tumor shrinkage and to provide patients with a clinically meaningful PFS benefit. Axitinib was superior to pazopanib [hazard ratio (HR) 0.64; 95 % credible interval (95 % Crl) 0.42–0.96] and sorafenib (HR 0.70; 95 % Crl 0.57–0.87) in terms of PFS. However, axitinib was associated with an elevated risk of fatigue and to a lesser extent stomatitis.

Conclusions

Keeping in mind the caveats associated with cross-trial statistical comparisons, axitinib provides superior PFS relative to pazopanib and sorafenib. Everolimus, an mammalian target of rapamycin inhibitor, is mechanistically distinct from the other agents and remains a useful option for patient’s post-anti-VEGFR TKI failure.

Keywords

Sorafenib Pazopanib Axitinib Everolimus Indirect comparison Renal cell carcinoma 

References

  1. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642–1649PubMedCrossRefGoogle Scholar
  2. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198–1220PubMedCrossRefGoogle Scholar
  3. Cai T, Parast L, Ryan L (2010) Meta-analysis for rare events. Stat Med 29:2078–2089PubMedCrossRefGoogle Scholar
  4. Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339PubMedCrossRefGoogle Scholar
  5. Di Lorenzo G, Casciano R, Malangone E et al (2011) An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 12:1491–1497PubMedCrossRefGoogle Scholar
  6. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in metastatic clear cell carcinoma. N Engl J Med 356:125–134PubMedCrossRefGoogle Scholar
  7. Escudier B, Eisen T, Stadler WM et al (2009a) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318PubMedCrossRefGoogle Scholar
  8. Escudier B, Szczylik C, Hutson TE et al (2009b) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289PubMedCrossRefGoogle Scholar
  9. Escudier B, Eisen T, Porta C et al (2012a) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii65–vii71PubMedCrossRefGoogle Scholar
  10. Escudier B, Szczylik C, Porta C, Gore M (2012b) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9:327–337PubMedCrossRefGoogle Scholar
  11. Grünwald V, Kalanovic D, Merseburger AS (2010) Management of sunitinib-related adverse events: an evidence and expert-based consensus approach. World J Urol 28:343–351PubMedCrossRefGoogle Scholar
  12. Hutson TE, Bellmunt J, Porta C et al (2010) Long-term safety of sorafenib in metastatic renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46:2432–2440PubMedCrossRefGoogle Scholar
  13. Larkin J, Paine A, Tumur I et al (2013) Second-line treatments for the management of metastatic renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 14:27–39PubMedCrossRefGoogle Scholar
  14. Levy A, Menard J, Albiges L, Loriot Y et al (2013) Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer 49:1898–1904PubMedCrossRefGoogle Scholar
  15. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRefGoogle Scholar
  16. Mills EJ, Rachlis B, O’Regan C, Thabane L, Perri D (2009) Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 27(9):34CrossRefGoogle Scholar
  17. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. New Engl J Med 335:865–875PubMedCrossRefGoogle Scholar
  18. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against metastatic renal cell carcinoma. J Clin Oncol 20:289–296PubMedCrossRefGoogle Scholar
  19. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463PubMedCrossRefGoogle Scholar
  20. Motzer MJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115–124PubMedCrossRefGoogle Scholar
  21. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in metastatic clear cell carcinoma: a double blind randomized placebo controlled phase III trial. Lancet 372:449–456PubMedCrossRefGoogle Scholar
  22. Motzer RJ, Escudier B, Tomczak P et al (2013) Axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trial. Lancet Oncol 14:552–562PubMedCrossRefGoogle Scholar
  23. National Cancer Institute of Canada (2012) Canadian Cancer Statistics 2012. Toronto, Canada (http://www.cancer.ca). Accessed 23 May 2013
  24. Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33:299–313PubMedCrossRefGoogle Scholar
  25. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in metastatic renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRefGoogle Scholar
  26. Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323–328PubMedCrossRefGoogle Scholar
  27. Sonpavde G, Hutson TE, Rini BI (2008) Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 17:741–748PubMedCrossRefGoogle Scholar
  28. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally metastatic or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRefGoogle Scholar
  29. Surveillance Epidemiology and End Results (SEER) (2013) National Cancer Institute 2012. Washington, USA (http://seer.cancer.gov/statfacts/html/lungb.html). Accessed 23 May 2013
  30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  31. Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122–127PubMedCrossRefGoogle Scholar
  32. Wong MK, Mohamed AF, Hauber AB et al (2012) Patients rank toxicity against progression free survival in second-line treatment of metastatic renal cell carcinoma. J Med Econ 15:1139–1148PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • George Dranitsaris
    • 1
    • 4
  • Susanne Schmitz
    • 2
  • Reuben J. Broom
    • 3
  1. 1.University of IoanninaIoanninaGreece
  2. 2.Trinity CollegeDublinIreland
  3. 3.Auckland City HospitalAucklandNew Zealand
  4. 4.TorontoCanada

Personalised recommendations